New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S.

Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry

100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.

The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators

Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk

Podium presentation showcases the clinical application of Precise™ MRD

Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating